The DOI matches its Crossref record; the references it cites are not checked yet.
Reduced Incretin Effect in Type 2 Diabetes
Abstract
We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state. Eight patients with chronic pancreatitis and secondary diabetes (A1C mean [range] of 6.9% [6.2-8.0]), eight patients with chronic pancreatitis and normal glucose tolerance (NGT; 5.3 [4.9-5.7]), eight patients with type 2 diabetes (6.9 [6.2-8.0]); and eight healthy subjects (5.5 [5.1-5.8]) were studied. Blood was sampled over 4 h on 2 separate days after a 50-g oral glucose load and an isoglycemic intravenous glucose infusion, respectively. The incretin effect (100% x [beta-cell secretory response to oral glucose tolerance test - intravenous beta-cell secretory response]/beta-cell secretory response to oral glucose tolerance test) was significantly (P < 0.05) reduced (means +/- SE) in patients with chronic pancreatitis and secondary diabetes (31 +/- 4%) compared with patients with chronic pancreatitis and NGT (68 +/- 3) and healthy subjects (60 +/- 4), respectively. In the type 2 diabetes group, the incretin effect amounted to 36 +/- 6%, significantly (P < 0.05) lower than in chronic pancreatitis patients with NGT and in healthy subjects, respectively. These results suggest that the reduced incretin effect is not a primary event in the development of type 2 diabetes, but rather a consequence of the diabetic state.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [18]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 40 · Cited by 349
Metadata
- Authors
- Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T.
- Affiliations
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Glostrup Hospital (DK)
- Hvidovre Hospital (DK)
- Novo Nordisk (Denmark) (DK)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-08-01
- Volume
- 56
- Issue
- 8
- Pages
- 1951-1959
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2104938107
- Cited by
- 349
- References
- 40
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 15 · 2023: 12 · 2022: 14 · 2021: 19 · 2020: 20 · 2019: 19 · 2018: 15 · 2017: 16 · 2016: 14 · 2015: 23 · 2014: 25 · 2013: 25 · 2012: 17
- FWCI
- 23.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin effect, type 2 diabetes, chronic pancreatitis, secondary diabetes, oral glucose tolerance test, type 2 diabetes pathogenesis, glucose-dependent insulin secretion
- MeSH terms
- Insulin Secretion, Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucagon, Glutaminase, Homeostasis, Humans, Insulin, Male, Middle Aged, Models, Biological, Intracellular Signaling Peptides and Proteins, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Incretin Effect in Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db07-0100
- The paper
- Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007). Reduced Incretin Effect in Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db07-0100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.